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t has been known that diseased/injured microenvironments release different biological cues and follow abnormal regulatory cycles when compared to physiologically normal cells and tissues.
1À3 Such dynamic microenvironmental conditions require scientists to develop more effective nanomaterial-based drug delivery systems (DDSs) having the following attributes: (i) they can deliver multiple drugs such as organic small molecules, proteins, peptides, DNA, and RNAi molecules without any physicochemical alterations to drug structure, 4À8 (ii) they can modulate the drug-release profile in response to external or internal stimuli for enhancing therapeutic efficacy and minimizing sideeffects of drug treatment, 9À15 and (iii) they can monitor the drug release in real time for investigating accumulation of the drugs at the targeted area. 16À21 In this regard, mesoporous silica nanoparticles (MSNs) have excellent potential as DDSs owing to their unique porous structure, tunable pore size, biocompatibility, ease of surface functionalization, and overall versatility. 22À24 The hexagonal-ordered pore network within these MSNs allows for entrapping drugs within these pores by simple diffusion. Additionally, the pores can be functionalized with molecular valves designed to trigger the release of the entrapped drugs in the presence of external or internal stimuli including light, 25À29 temperature, 30À32 pH, 33À37 and biomolecules. 38À42 While there have been numerous reports on the design and development of stimuliresponsive MSNs for drug delivery, development of strategies for real-time monitoring of drug release inside the targeted cells is still in its nascent stage. The most widely used among these strategies include using fluorescent dyes/drugs as a model cargo system, 18À35 or conjugating the drugs with caged dyes. 19, 20 However, such strategies come with their own limitations such as difficulty in correlating the release of the fluorescent model dye to that of the actual drug molecules; restricting the usage of fluorescent drugs like doxorubicin as model cargoes, although most of the current drug candidates are nonfluorescent; and the possibility of affecting the therapeutic efficacy of the drug owing to structural changes required for conjugation of dyes. Such challenges in investigating the release of drug in complex cellular microenvironments necessitate the development and integration of a real-time monitoring system within the stimuliresponsive nanomaterial-based DDSs.
To address the aforementioned issues, herein we describe the synthesis and development of a redoxresponsive fluorescent resonance energy transferbased MSN drug delivery system (henceforth referred to as FRET-MSN), which enables real-time monitoring (based upon the FRET signal) of redox-responsive drug release occurring in the presence of glutathione found in significantly higher levels in the cancer cells ( Figure 1 ).
43À45 Fluorescence resonance energy transfer (or Förster resonance energy transfer, FRET) is a well-established energy transfer process between two fluorophores which is very sensitive to changes at the nanometer-scale (typically less than 10 nm) in the donor-to-acceptor separation distance. 46 This unique feature of FRET can potentially be an ideal tool to monitor delicate interactions between nanomaterialbased DDSs and external/internal stimuli. 47, 48 As illustrated in Figure 1 , our FRET-based real-time monitoring platform comprises four components: (i) coumarin (donor)-tethered MSNs as the drug carriers, The coumarin-labeled cysteine on the surface of the FRET-MSNs act as a donor and the FITC-β-CD act as an acceptor, thereby forming a FRET system when the disulfide bond is intact (left). When the disulfide bond is cleaved in the presence of redox stimuli, glutathione, the FITC-β-CD, which also acts as the molecular valve, is removed from the surface of the MSNs, thereby the FRET between coumarin and FITC is abolished.
(B) The delivery of encapsulated cargo is selectively triggered in the presence of the redox-stimuli, glutathione which is found in significantly higher amounts in the cytoplasm of cancer cells and the concomitant change of FRET signal can be used to report the uncaging event and estimate the dosing amount of drug. Figure 1A is a magnified representation of Figure 1B 
RESULTS AND DISCUSSION
Synthesis and Characterization of FRET-MSNs. The generation of our FRET-MSN-based drug delivery system began with the synthesis of MCM-41type MSNs via condensation of tetraethylorthosilicate (TEOS) in the presence of a cetyltrimethylammonium bromide (CTAB) micelle template ( Figure 2A ). 50 These MSNs were then The thiol group of cysteine was conjugated with 1-adamantanethiol to form a redox-responsive disulfide bond, while the amine group was further labeled with 3-carboxy-7-hydroxyl-coumarin (CHC) to obtain the functional CHC-MSNs. Using transmission electron microscopy (TEM), we affirmed that the CHC-MSNs still retain the characteristics of MCM-41 type of MSNs, such as their spherical particle shape, having an average diameter of 100 ( 14 nm (n = 100) and hexagonally packed mesoporous structures ( Figure 2B ). This was also substantiated by N 2 adsorption isotherms which demonstrated that the CHC-MSNs have a BurnauerÀ EmmettÀTeller (BET)-surface area of 398 m 2 3 g À1 and a narrow BarrettÀJoynerÀHalenda (BJH) pore-size distribution (average pore diameter = 2.3 nm) (see Supporting Information, Figure S2 ). In addition, the cysteine functionalized MSNs show a characteristic Raman peak of free thiol group 51 at 2550 cm À1 ( Figure 2C , top curve).
However, after conjugation with 1-adamantanethiol via a disulfide bond, this characteristic free thiol peak disappeared, which confirmed the formation of a disulfide bond ( Figure 2C bottom curve). Figure 2D shows the UVÀvis absorption and fluorescence emission of CHC-MSNs, demonstrating the successful conjugation of CHC to the MSN surface and indicates that the CHC-moiety can act as the energy donor for FITC (see Supporting Information, Figure S4 ). Together with the FTIR characterization of CHC-MSNs (see Supporting Information, Figure S3 ), these results demonstrated the successful construction of CHC-MSNs. Assembly of a DonorÀAcceptor FRET Model. The synthesis of FRET-MSNs was then followed by the combination of the CHC-MSNs with FITC-β-CD via hostÀguest complexation between FITC-β-CD and adamantane moiety 52 present on CHC-MSNs ( Figure 3A ). As shown in Figure 2D , the coumarin moiety in CHC-MSNs can be excited by absorbing light with a wavelength of 405 nm, resulting in emission of light in the range of 430À480 nm. When the disulfide bond is intact (Figure 1 ), the coumarin moiety in CHC-MSNs upon excitation at 405 nm will act as a photon donor for the FITC-β-CD which absorbs maximally at 480 nm (see Supporting Information, Figure S4 ). We observed that the addition of FITC-β-CD leads to a decrease in blue fluorescence (450 nm) and an increase in green fluorescence (520 nm) ( Figure 3B ), which was also reflected in a significant change of the color of the solution from blue to green, sufficiently distinct to be identified via the naked eye ( Figure 3A , inset). As seen in Figure 3B , further increases in the concentration of FITC-β-CD ARTICLE quenched the blue fluorescence maximally. Additionally, from the data shown in Figure 3B , the ratio of relative fluorescence intensities (FRET signal R, where R = F 520 nm /F 450 nm ) reached a value of 1.25 at a concentration of 3 μM for FITC-β-CD for a fixed concentration of CHC MSNs (10 μg 3 mL À1 ), which indicated the assembly of FITC-β-CD to the MSN surface reached a saturation point. Further addition of FITC-β-CD beyond the saturation point only led to an increase in the FITC fluorescence with negligible quenching of coumarin fluorescence, presumably due to the direct excitation of FITC at 405 nm. 46 When these nanoparticles were isolated from the solution and redispersed in PBS (pH 7.4), they displayed dual emission peaks at 450 and 520 nm upon excitation at 405 nm (see Supporting Information, Figure S5a) . Collectively, these results demonstrated that FITC-β-CD can assemble onto the surface of the CHC-MSN surface through the formation of inclusion complex with 1-adamantanethiol, thereby inducing a donorÀacceptor FRET system. Redox-Responsive Behavior of FRET-MSNs. The redoxresponsive property of the FRET-MSNs was examined by observing the changes in FRET signal in the presence of glutathione (GSH) which mimics the intracellular reducing environment ( Figure 3A ). As shown in Figure 3C , the addition of increasing concentrations of GSH (0.1À5 mM) to a buffered solution of FRET-MSNs induced a decrease in the green fluorescence (520 nm) accompanied by recovery of blue fluorescence (450 nm) upon excitation at 405 nm. This strongly indicated the cleavage of disulfide bond and the removal of the FRET acceptor, FITC-β-CD. Accordingly, the color of the solution changed from green to blue under UV lamp (365 nm) ( Figure 3A, inset) . Fluorescence spectrum of the isolated nanoparticles after redispersing in PBS (pH 7.4) revealed that these nanoparticles only show the emission at 450 nm (see Supporting Information, Figure S5b ). On the basis of these results, we can confirm the redox-responsive behavior of our FRET-MSNs, which results in a concomitant change in the FRET signal.
Correlating Drug Release from FRET-MSNs to the FRET Signal. Once we confirmed the redox-responsive gating behavior of our FRET-MSNs, our next step was to utilize their FRET properties for monitoring the drug release from the pores. Since the modulation of FRET is integrated within the uncapping event, we hypothesize that the corresponding change in the FRET signal can be utilized for monitoring the drug release on a temporal level ( Figure 4A ). To demonstrate this, we chose doxorubicin (DOX) as our model cargo, which was loaded into the pores of MSNs by first mixing aqueous buffered solutions of CHC-MSNs and DOX for 12 h. Thereafter, the pores were capped with FITC-β-CD ARTICLE and the final product (DOX-loaded FRET-MSNs) was isolated by centrifugation after repeated washing. The amount of DOX loaded into the pores of FRET-MSNs was determined to be 41.3 mg DOX/g of FRET-MSNs. It should be noted that the DOX-loaded FRET-MSNs were well-dispersed in aqueous solutions, owing to the presence of hydrophilic β-CD moieties on their surface, which can be exploited for the delivery of hydrophobic cargoes, like anticancer drugs. 53 To investigate the capping efficiency, DOX-loaded FRET-MSNs were dispersed in PBS (pH 7.4) and the absorbance of the released DOX in the absence of GSH was first monitored. As shown in Figure 4B (curve a), negligible release of DOX was observed over a period of 24 h, indicating that the FRET-MSNs remain intact in the absence of GSH. In contrast, the release profiles of DOX in the presence of varying concentrations of GSH depict an increase in the percent DOX released as time progressed ( Figure 4B , curve bÀd). From Figure 4B , we can see that the percent DOX released from the FRETMSNs was dependent on GSH concentration, wherein concentrations of 0.1 mM or higher lead to significantly faster and greater release of DOX. Since the release of DOX only occurs when the pores are unlocked as a consequence of FITC-β-CD diffusing away from the FRET-MSNs, we also observed a corresponding change in the FRET signal R. As shown in Figure 4C , the addition of GSH (0.1 mM) to Dox-loaded FRET-MSNs induced a relatively slow time-dependent decrease in the FRET signal over a period of 3 h, while higher concentrations of GSH lead to a faster decrease in the FRET signal, reaching a minimal value of R within 1 h at 5 mM concentration of GSH. These GSH-concentration induced changes in the FRET signal remained constant over a period of 24 h, at which the release of DOX also reached a plateau. From this data (t = 24 h), a correlation between the amount of DOX released and FRET signal R was obtained ( Figure 4D ), which strongly suggested that the FRET-MSNs have the capability of monitoring the drug release in real-time.
Observing FRET Change in Cancer Cells Using FRET-MSNs. Prior to using the FRET-MSNs for cellular studies, we identified a range of concentrations within which the FRET-MSNs demonstrated minimal cytotoxicity (see Supporting Information, Figure S6 ). Using a cell proliferation assay, we found that concentrations lower than 20 μg 3 mL À1 induced negligible cytotoxicity in HeLa cells, and hence for all of our experiments, we utilized FRET-MSNs within this concentration range. To investigate the change in FRET signal following uptake and localization of FRET-MSNs in mammalian cells, we incubated the FRET-MSNs with cervical cancer cells (HeLa) and observed the change in FRET signal over extended periods of time (0À24 h) using confocal fluorescence microscopy. As seen in Figure 5A (top left), at time t = 0 h, blue-green spots were visible in the perinuclear region of HeLa cells when they were excited using 405 nm light, indicating intact FRETMSNs with the FRET signal ON. From the emission spectrum ( Figure 5A , top right), we can see that these spots show lower blue emission, but stronger green emission thus confirming that most of the FRET-MSNs were in the "FRET ON" stage at this time-point. However, at approximately t = 24 h, an increase in the blue fluorescence intensity and a corresponding decrease in the green fluorescence intensity ( Figure 5A , bottom left) were observed when the cells were excited using 405 nm light. This was consistent with our expectation as the cleavage of disulfide bond would lead to the removal of FITC-β-CD cap, thereby leading to the recovery of the blue fluorescence intensity ( Figure 5A , bottom right). The removal of the FITC-β-CD cap was further confirmed by observing diffuse FITC fluorescence throughout the cytoplasm, when the cells were excited using the FITC channel (488 nm) (see Supporting Information, Figure S8 ). These results demonstrated that we were able to monitor the change in the intracellular FRET signal over a period of time by using confocal microscopy.
As shown earlier, we have already demonstrated that our FRET-MSNs can respond to the presence of exogenous GSH by releasing the entrapped cargo with concurrent change in the FRET signal. However, to demonstrate this in mammalian cells, we used thioctic acid (TA, a GSH synthesis enhancer, 10 μM) 54 and N-ethylmaleimide (NEM, a GSH scavenger, 5 μM) 55, 56 to modulate the intracellular GSH concentration. The HeLa cells were incubated with TA and NEM, 10 min prior to incubation with the FRET-MSNs and were subsequently analyzed using fluorescence microscopy. As depicted in Figure 5B , we observed a clear enhancement in the characteristic coumarin emission at 450 nm for the cells treated with TA in FRET channel (Ex = 405 nm), coupled with increased FITC fluorescence in FITC channel (Ex = 488 nm), indicating that higher number of the molecular valves (FITC-β-CD) were being removed from the surface of FRET-MSNs due to increased intracellular GSH concentration and were subsequently diffused into the cytoplasm. On the contrary, a distinct punctate blue-green fluorescence in the FRET channel, indicating FRET ON, was seen in the perinuclear region in case of cells treated with NEM. Since NEM decreases intracellular GSH concentration, there will be negligible cleavage and subsequent release of FITC-β-CD, hence resulting in the FRET being ON. As seen in Figure 5C , quantitative analysis of the relative intensities of coumarin emission (Ex = 405 nm. Em = 450 nm) also showed a similar trend of increasing coumarin emission as the intracellular GSH concentration increased. On the basis of these results, we were also able to confirm that the release of the molecular gate (FITC-β-CD) occurred in response to the redox stimuli, GSH present in millimolar levels in the cytoplasm of cancer cells.
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Monitoring Drug Release in Real-Time in Cancer Cells Using FRET-MSNs. However, it is important to demonstrate if we can correlate this change in the FRET signal with the corresponding drug release and its downstream therapeutic efficacy. To prove this, we treated HeLa cells with TA and NEM to modulate the cytoplasmic GSH concentration prior to the addition of DOX-loaded FRET-MSNs, and the viability of HeLa cells was monitored 24 h after treatment. The change in intracellular GSH concentration will result in a change in the extent of disulfide bond cleavage, which shall be displayed as a change in the FRET signal R as well as the amount of DOX released. Since the amount of DOX released from the nanoparticles influences the viability of cells, we can then correlate the change in FRET signal with the cell viability. As expected, the presence of TA, which increased the intracellular GSH concentration, led to an increase in the unlocking of pores which was associated with a decrease in the cell viability as well as an decrease in the FRET signal, R (thus 1/R increases as seen in Figure 5D , FRET OFF). In contrast, when the cells were pretreated with the GSH scavenger, NEM, we observed an increase in the cell viability as well as a increase in the FRET signal ratio, R (thus 1/R decreases as seen in Figure 5D, FRET ON) . These results demonstrated the ability of our proposed FRET-MSNs based DDS in real-time monitoring drug release and reporting cell viability. 
CONCLUSIONS
In summary, we have successfully demonstrated the formation of redox-responsive fluorescent MSNs, comprising an integrated FRET-based real-time monitoring system, which enabled tracking the release of the payload from the pores of the MSNs in real-time, by measuring the change in the FRET signal. We have shown a good correlation between the change in the FRET signal and the extent of drug released at different GSH concentrations both at the solution level as well as inside the cells. The advantage of our platform is that it can be extended to any cargo, fluorescent or nonfluorescent, as the molecular structures responsible for realtime monitoring are integrated within the unlocking mechanism present on the nanoparticle, and hence, we do not need to rely on the optical properties of the drug or a model dye. As such, we can monitor the release of the cargo on a temporal level, even if the drug is nonfluorescent, thus demonstrating the versatility of our platform. Additionally, no structural modification of the drug is required as the donorÀacceptor pair is integrated within the nanoparticles, thereby preserving the drug efficacy. Numerous studies have demonstrated significantly higher intracellular glutathione concentrations in cancer cells as compared to normal cells, we can expect our FRET-MSNs to release the biomolecules more selectively in cancer cells. However, we can expect to extend the applications of the FRET-MSNs to any trigger such as pH or temperature by making appropriate structural modifications, since the FRET signal only depends on the donorÀacceptor pair. Thus, we can envision our realtime monitoring system would provide a unique and universal strategy for overcoming the challenges encountered in the tracking (location) and monitoring (time) of drug release over extended periods of time and shows great potential for bioapplications, such as the investigation of cancer stem cells and effective therapies against them. However, a more advanced real-time monitoring system should also possess the capability of achieving direct monitoring of the release kinetics of drugs. Hence, we will explore additional avenues for enabling our FRET-MSNs to precisely monitor the kinetics of drug release as our future goals.
METHODS
Synthesis of FRET-MSNs. NH 2 -MSNs.
50
. In a typical synthesis procedure, 28 mg of sodium hydroxide and 100 mg of cetyl trimethyammonium bromide (CTAB) in sequence were completely dissolved into 50 mL of deionized water under vigorous stirring at 80°C. After the solution became clear, 0.5 mL of TEOS was added dropwise in 10 min. After 3 h, 20 μL of APTES was added and the vigorous stirring was continued for 20 h, and then milk-white as-synthesized materials were collected by centrifugation. To remove the surfactant, the as-synthesized materials were refluxed in a solution consisting of 50 mL of ethanol and 0.5 mL of hydrochloric acid (36À38%) for 12 h, centrifuged and finally washed several times with methanol. The final products were dried for 12 h at 120°C in vacuum.
Cys-MSNs. To a solution of N-Boc-cysteine (22 mg) and N-hydroxysuccinimide (NHS, 25 mg) in 5 mL of anhydrous DMF at 0°C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC 3 HCl, 31 mg) was added. The solution was stirred at 0°C for 30 min and recovered to room temperature for additional 4 h. Then 100 mg of NH 2 -MSNs in 5 mL of DMF solution was added slowly and the mixture was keep stirring overnight under N 2 . The nanoparticles were collected by centrifugation and washed several times with DMF and methanol, and finally dried in vacuum to obtain Cys-MSNs.
Cys-TA-MSNs. A solution of Cys-MSNs (80 mg) in 5 mL of methanol was added dropwise into a solution of 2,2 0 -dithiodipyridine (0.1 g) in methanol/pH7.4 PBS solution (v/v, 10 mL/1.5 mL). The mixture was stirred at room temperature overnight and the nanoparticles were collected by centrifugation, washed thrice with methanol and finally redispersed in 10 mL of methanol. 1-Adamantanethiol (0.1 g) in 2 mL of methanol was then added to the above solution and the mixture was stirred overnight at room temperature under N 2 atmosphere. The Cys-TA-MSNs were collected by centrifugation, washed several times with methanol, and then dried under vacuum.
CHC-MSNs. A 5 mL portion of DCM solution of Cys-TA-MSNs (60 mg) was cooled to 0°C for 30 min, and then 2 mL of trifluoroacetic acid (TFA) was added. The mixture was stirred at 0°C for 30 min and then recovered to room temperature for an additional 3 h. Then 10 mL of methanol was added to dilute the mixture. The nanoparticles were collected by centrifugation and washed several times with methanol, dried in vacuum, and finally redispersed in 5 mL of anhydrous DMF. To a solution of 7-hydroxycoumarin-3-carboxylic acid (100 mg) and NHS (80 mg) in 5 mL of anhydrous DMF at 0°C, 70 mg of EDC 3 HCl were added. The solution was stirred at 0°C for 30 min and recovered to room temperature for an additional 4 h. Then, the 5 mL of DMF solution consisting of TFA-treated Cys-TA-MSN nanoparticles was added slowly to the solution and the mixture was keep for stirring overnight. The nanoparticles were collected by centrifugation and washed several times with DMF and methanol, and then finally dried in vacuum to obtain the CHC-MSNs.
Synthesis of FITC-β-CD. Mono-6-deoxy-6-amino-β-cyclodextrin (NH 2 -β-CD) was first synthesized by a previously reported method. À . An amount of 38 mg of FITC along with 10 mg of DMAP and 0.1 g of NH 2 -β-CD was added into 5 mL anhydrous DMF and the solution was stirred overnight at room temperature under N 2 . A 10 mL portion of acetone was added to the solution and the precipitate was collected and washed with acetone several times.
Characterizations. UVÀvis absorption spectra were recorded on a Varian Cary 50 spectrophotometer. Fluorescence spectra were recorded on a Varian Cary Eclipse fluorescence spectrophotometer. FT-IR spectra were collected on an Avatar Nicolet FT-IR330 spectrometer. Raman spectrum characterizations were performed on Laser Raman, Renishaw inVia Raman microscope. 1 H NMR was acquired on Varian 300 MHz NMR spectrometer. ESI-MS was collected on Finnigan LCQ DUO LC/MS spectrometer. TEM was performed on a Topcon 002B electron microscope at 200 kV. Sample preparation was carried out by placing a drop of the freshly prepared colloidal solution on a carbon-coated copper grid and allowing the solution to evaporate. Nitrogen adsorptionÀdesorption measurements were performed on a Micromeritics Tristar-3000 surface area analyzer at À196°C. The sample was dried at 200°C for 3 h before analysis. The BET specific surface areas were calculated using the first 10 experimental data points. Pore volumes were determined from the amount of N 2 adsorbed at the single point, P/P 0 = 0.98.
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Cell-Lines and Culture. HeLa cells were used for FRET-MSNs. HeLa cells were cultured in DMEM supplemented with 10% FBS and 1% streptomycinÀpenicillin. For the delivery experiment, passaged cells were prepared to 40À60% confluency in 24-well plates. After 24 h of plating, media was exchanged with serumfree basal media (500 μL) and FRET-MSNs/X-tremeGENE complexes (50 μL) were added. After incubation for 6 h, media was exchanged with normal growth medium. Fluorescence measurements were performed after 0À24 h after transfection.
Imaging of FRET-MSNs. At different time points following transfection, the cells were imaged using fluorescent microscopy. The effect of GSH concentration on the FRET signal was studied using the eplifluorescence microscopy. For this purpose, the fluorescent and phase contrast images were obtained using the Nikon T2500 inverted epifluorescence microscope. Each image was captured with different channels and focus. Images were processed and overlapped using Image-Pro (Media Cybernetics) and ImageJ (NIH). To monitor and quantify the change in FRET signal in vitro, confocal imaging was done using a Zeiss LSM 510-META confocal microscope equipped with an Axiovert 200 inverted Scope.
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